5.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$5.96
Aprire:
$5.92
Volume 24 ore:
479.46K
Relative Volume:
1.08
Capitalizzazione di mercato:
$351.22M
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-2.5491
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
-3.22%
1M Prestazione:
+20.46%
6M Prestazione:
+3.44%
1 anno Prestazione:
+29.77%
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta GLUE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
GLUE
Monte Rosa Therapeutics Inc
|
5.71 | 366.60M | 0 | -130.41M | -67.76M | -2.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-02-15 | Iniziato | Wedbush | Outperform |
2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2022-10-13 | Iniziato | UBS | Buy |
2022-08-15 | Iniziato | Jefferies | Buy |
2022-04-28 | Iniziato | Credit Suisse | Neutral |
2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional
What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewswire
First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan
Monte Rosa (GLUE) Soars 13.58% in Three Days, Hits 2025 High - AInvest
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Monte Rosa Therapeutics Inc (GLUE) Stock: A Year of Market Movement, Down and Up - investchronicle.com
How Monte Rosa Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - beatles.ru
What makes Monte Rosa Therapeutics Inc. stock price move sharplyFree Consultation - Newser
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention2x 3x 5x Pick Alert - Newser
With surface mimicry, molecular glues shed hairpin need - BioWorld MedTech
Monte Rosa Therapeutics (GLUE) Soars 4.55% on Clinical Trial Progress - AInvest
Monte Rosa Therapeutics (GLUE): Pioneering the Future of Drug Discovery with Molecular Glue Degraders - AInvest
Monte Rosa Therapeutics Announces Publication of Landmark Research on Molecular Glue Degraders in Science - Nasdaq
Monte Rosa Announces Publication in Science of Key Insights - GlobeNewswire
Monte Rosa Announces Publication in Science of Key Insights That Enable Next Generation Molecular Glue Degrader Medicines - MarketScreener
Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition - Science | AAAS
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):